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were enrolled. Only 4.5% were not assessable and 659 (86.5%)
were able to answer the SATMED-Q. The oretical 6 factor solu-
tion explained 82.8% of the available variance; it was well
deﬁned, and all communalities were above 0.76. A strong cor-
relation between Effectiveness and Impact on Daily Activities 
(r = 0.525) was found. Dimensional Cronbach’s á ranged
between 0.857 and 0.936. The one-dimensional ICC was 0.893
(0.890–0.905, 95% CI) and Guttman two-half index was 0.935.
No signiﬁcant correlation was found between age and Treatment
Satisfaction (r = 0.055), Anxiety (r = −0.17), and Depression 
(r = 0.075). Neither between educational level and Anxiety (r =
−0.038), but educational level showed to be related with Depres-
sion (r = −0.204; p < 0.001) and Treatment Satisfaction (r =
0.169; p < 0.001). Treatment Satisfaction dimension levels inter-
act signiﬁcantly with Depression (p < 0.001) and Anxiety (p <
0.011) severity levels. CONCLUSIONS: The psychometric prop-
erties of the SATMED-Q are good in this speciﬁc population.
Signiﬁcant differences in Treatment Satisfaction are found
depending on the Anxiety and Depression level.
PND14
TREATMENT OF NEUROPATHIC PAIN IN MULTIPLE
SCLEROSIS: A POPULATION BASED WILLINGNESS-TO-PAY
ANALYSIS
Iskedjian M1, Piwko C1, Desjardins O1, Bereza B1, Jaszewski B2,
Einarson TR3
1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada,
2Bayer Healthcare,Toronto, ON, Canada, 3University of Toronto,
Toronto, ON, Canada
OBJECTIVES: Multiple Sclerosis (MS) is a chronic neurological
disease affecting the central nervous system with a prevalence
rate of 240 per 100,000 in Canada. The prevalence of pain in
MS ranges from 10%–80% (70% in a study we previously per-
formed). Sativex® (SAT) is a new cannabis-based drug approved
in Canada for neuropathic pain in patients with MS. Willing-
ness-to-pay (WTP) elicits the extent of subjects’ preference for
their chosen treatment, expressed as the amount they would
hypothetically be willing to pay in insurance premiums in order
to have access to the treatment. METHODS: The WTP instru-
ment had a decision board (DB) and a questionnaire. A DB is a
visual aid to help clinicians present clinical information about
treatment options in a standardized manner. Two treatment
options were presented on the board used in this study, with text
and data describing them obtained from clinical experts and the
literature. The ﬁrst option was a “cocktail” of three medications:
gabapentin, amytriptylin, and acetaminophen (“pills”), while the
comparator was the same “cocktail” but adding SAT (“pills and
oral spray”). The WTP instrument was administered to 500 par-
ticipants from the general Canadian population, using the
bidding game approach. Descriptive statistics were calculated.
RESULTS: The mean age of the study population was 39 ± 13
years, 56% were female. The DB was facilitated in English
(85%) and French (15%). Of the 500 interviews conducted, 253
respondents chose the “pills and oral spray” option. For these
subjects, the mean WTP per month in additional insurance
premium was CAD $8 (range = $0–$200, median = $4). CON-
CLUSION: Assuming only 51% in a general population are
willing to pay additional premiums as reported, the obtained
WTP would be able to fund the drug for all MS patients with
pain (assumed 70%), with a remaining surplus of $3.24/person.
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OBJECTIVES: This study used a stated preference discrete
choice experiment (DCE) to explore the preferences and will-
ingness to pay (WTP) of RR-MS patients in the UK regarding
the beneﬁts of treatments. METHODS: The attributes in the
DCE included the number of future relapses, presence of new
nerve damage, progression in disability level and out of pocket
cost (to estimate WTP for changes in attribute levels). Partici-
pants were asked to indicate their preference for hypothetical
treatment proﬁles that varied attribute levels based on an orthog-
onal fold-over design. The patient sample (n = 194) was recruited
through advertisement with a patient advocacy group. WTP was
estimated using logit analysis. RESULTS: Eighty-three percent of
patients (mean age 44 years, 82% female) had experienced 1 or
more relapses in the last 2 years and 46% required aid with
ambulation. Patients had a mean annual household income of
≤33,000 and monthly MS-related expenditures of approximately
≤50. The estimated monthly WTP for a combined beneﬁt of 
no disability progression, new nerve damage or relapses was
approximately 9 times their current expenditures and 16% of
their mean annual income. The most highly valued treatment
outcome was avoidance of disability progression in the next year.
Segmented analyses indicated that patients not currently experi-
encing a relapse and those with lower self-reported levels of dis-
ability had higher WTP for improvements in the other treatment
beneﬁt attributes. CONCLUSION: RR-MS patients indicated a
differential demand for avoidance of MS related disability pro-
gression, relapses and nerve damage. Patients who were less
severely affected by their RR-MS were willing to pay more to
reduce the burden of their disease. This study underlines the high
value patients place on the avoidance of MS sequelae, particu-
larly disability progression.
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OBJECTIVES: Aim of our study is to analyse the 30 days mor-
tality of patients over 60 with femoral neck fracture according
to comorbidities at admission. METHODS: Data derives from
the database of National Health Insurance Fund Administration
and based on the S7200 code (femoral neck fracture) of Inter-
national Classiﬁcation of Diseases (ICD) tenth revision and the
codes of comorbidities. The retrospective study is based on
patients discharged in 2000 from the institutions providing deﬁn-
itive care after the primary treatment of femoral neck fracture.
Financial data has been controlled with a nationwide institu-
tional questionnaire. We calculated 30 days mortality as a time
between hospital admission and death. Early mortality rates are
presented according to the dominant occurrence most frequently
found comorbidities. RESULTS: Altogether 3783 patients over
60 years met the inclusion criteria. The overall 30 days mortal-
ity was 9%. The mortality of patients with comorbidities was
9.65%, while without comorbidities it was 2.1%. The early mor-
